-
1 Comment
Takara Bio Inc is currently in a long term downtrend where the price is trading 1.2% below its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.9.
Takara Bio Inc's total revenue rose by 49.9% to $12B since the same quarter in the previous year.
Its net income has increased by 445.3% to $3B since the same quarter in the previous year.
Finally, its free cash flow grew by 280.3% to $1B since the same quarter in the previous year.
Based on the above factors, Takara Bio Inc gets an overall score of 4/5.
| ISIN | JP3460200003 |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | F |
| CurrencyCode | EUR |
| Market Cap | 604M |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | 0.44 |
| Dividend Yield | 4.3% |
Takara Bio Inc., together with its subsidiaries, engages in bioindustry, contract development and manufacturing organization (CDMO), and gene therapy businesses in Japan, China, rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including genetic research reagents and testing kits; products related to coronavirus testing comprising in vitro diagnostics that detect viruses; analytical reagents; single-cell analysis systems; gene expression research reagents; fluorescent proteins series; genome-editing research reagents; iPS cell research reagents; and products for stem cell culturing and induction of differentiation under the TaKaRa, Clontech, and Cellartis brand names. It also provides contract services for regenerative medicine products, such as manufacturing of viral vectors and gene-transduced cells, quality and safety testing, and cell banking; and contract services for gene analysis and testing, including sequencing, intestinal flora analysis, comprehensive analysis of cancer-associated genes, and cell line creation through genome editing. In addition, the company is involved in developing platform technology for biologics development in areas, such as gene therapy. The company was incorporated in 2002 and is based in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for TF2.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
